News and Events – Page 2 – COD Research

WDSC-Web-Upcoming

6 months ago

WDSC upcoming

Posted by cppl_codresearch_2022

Bio-2024-Attendee-Web-01_ Upcoming

Bio 2024 upcoming

World Drug safety Congress Europe 2023 in Amsterdam, Netherlands

DIA 2023 in Boston, Massachusetts

CODE Exhibiting at BIO 2024

DCAT 2023 in New York City

Scope 2023 in Orlando, Florida

Events

2 years ago

May the celebratory nights of Navaratri brighten up your year.

Events

2 years ago

Glimpse of Diwali Celebration at our office.

Featured

2 years ago

Scope 2023 in Orlando, Florida

CODE Exhibiting at BIO 2024

Featured

2 years ago

DCAT 2023 in New York City

Featured

2 years ago

DIA 2023 in Boston, Massachusetts

Featured

2 years ago

World Drug safety Congress Europe 2023 in Amsterdam, Netherlands

Bio-2024-Attendee-Web-01_ Upcoming

Featured

6 months ago

Bio 2024 upcoming

WDSC-Web-Upcoming

Featured

6 months ago

WDSC upcoming

Orphan designation: Autologous haematopoietic cells genetically modified with a lentiviral vector containing the human gp91(phox) gene Treatment of X-linked chronic granulomatous disease, 09/02/2012 Positive
Source: EMA Published on 2024-11-01
Guidance on the application of the amended Variations Regulation from 1 January 2025
Source: EMA Published on 2024-10-31
PSUSA/00010097/202403
Source: EMA Published on 2024-10-31
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28-31 October 2024
Source: EMA Published on 2024-10-31
PSUSA/00010245/202403
Source: EMA Published on 2024-10-31
PSUSA/00010809/202403
Source: EMA Published on 2024-10-31
PSUSA/00010098/202403
Source: EMA Published on 2024-10-31
PSUSA/00001614/202403
Source: EMA Published on 2024-10-31
PSUSA/00010002/202403
Source: EMA Published on 2024-10-31
Parallel distribution: Regulatory and procedural guidance
Source: EMA Published on 2024-10-31
List of centrally authorised products with safety-related changes to the product information
Source: EMA Published on 2024-10-31
Orphan designation: Adeno-associated viral vector serotype 1 containing the 3' portion of human OTOF gene, Adeno-associated viral vector serotype 1 containing the 5' portion of human OTOF gene Treatment of otoferlin gene-mediated hearing loss, 20/03/2023 Positive
Source: EMA Published on 2024-10-31
Orphan designation: Cemdisiran Treatment of primary IgA nephropathy, 20/08/2021 Positive
Source: EMA Published on 2024-10-31
Orphan designation: Rivoceranib (mesilate) Treatment of hepatocellular carcinoma, 27/09/2024 Positive
Source: EMA Published on 2024-10-31
Orphan designation: efineptakin alfa Treatment of acute radiation syndrome, 30/09/2024 Positive
Source: EMA Published on 2024-10-31

Know Which Medication Is Right for Your Seasonal Allergies
Source: FDA Published on 2024-06-25
Sani-Care Salon Products, Inc. - 673747 - 04/24/2024
Source: FDA Published on 2024-06-25
Glenmark Pharmaceuticals Inc., USA Issues Voluntary Nationwide Recall for Potassium Chloride Extended-Release Capsules, USP (750 mg) 10 mEq K Due to Failed Dissolution
Source: FDA Published on 2024-06-25
Report | Drug Shortages: Root Causes and Potential Solutions
Source: FDA Published on 2024-06-24
FDA approves treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults
Source: FDA Published on 2024-06-24
Facilitating Generic Drug Product Development through Product-Specific Guidances - 04/25/2024
Source: FDA Published on 2024-06-24
Modernizing the New Drugs Regulatory Program
Source: FDA Published on 2024-06-24
FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
Source: FDA Published on 2024-06-21
Public Workshop: Best Practices for Meeting Management Under PDUFA VII - 07/22/2024
Source: FDA Published on 2024-06-21
Center for Drug Evaluation and Research National Survey on Numerical Claims in Prescription Drug Advertising
Source: FDA Published on 2024-06-20
Infla-650 contains hidden drug ingredients
Source: FDA Published on 2024-06-20
Cefdinir - Oral products
Source: FDA Published on 2024-06-20
Considerations in Demonstrating Interchangeability With a Reference Product: Update
Source: FDA Published on 2024-06-20
Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection
Source: FDA Published on 2024-06-20
FDA updates guidance on interchangeability
Source: FDA Published on 2024-06-20

Field Safety Notices: 30th October 2024
Source: MHRA Published on 2024-10-30
Class 2 Medicines Recall: Tillomed Laboratories Limited, Labetalol 200mg Tablets, EL(24)A/52
Source: MHRA Published on 2024-10-29
Field Safety Notices: 21 to 25 October 2024
Source: MHRA Published on 2024-10-29
Class 4 Medicines Defect Information: Kent Pharma UK, Parasolve (Paracetamol) 500mg effervescent tablets, EL(24)A/51
Source: MHRA Published on 2024-10-28
Class 2 Medicines Recall: Bristol Laboratories Ltd, Phenobarbital Bristol Labs 15mg Tablets, EL(24)A/50
Source: MHRA Published on 2024-10-23
Field Safety Notices: 14 to 18 October 2024
Source: MHRA Published on 2024-10-22
Class 4 Medicines Defect Information: Kent Pharma UK, Paracetamol 500mg Effervescent Tablets, EL(24)A/49
Source: MHRA Published on 2024-10-21
Field Safety Notices: 18 October 2024
Source: MHRA Published on 2024-10-18
Field Safety Notices: 7 to 11 October 2024
Source: MHRA Published on 2024-10-16
Field Safety Notices: 7 October to 14 October 2024
Source: MHRA Published on 2024-10-11
Class 4 Medicines Defect Information: Sandoz Ltd., Linezolid 600 mg film-coated tablets, EL(24)A/48
Source: MHRA Published on 2024-10-10
Class 3 Medicines Recall: Viatris UK Healthcare Ltd, Trandolapril 2mg and 4mg capsules, EL(24)A/47
Source: MHRA Published on 2024-10-07
Field Safety Notices: 30 September to 4 October 2024
Source: MHRA Published on 2024-10-04
Class 3 Medicines Recall: Glenmark Pharmaceuticals Europe Ltd Cyanocobalamin 50 mcg Tablets, EL(24)A/46
Source: MHRA Published on 2024-10-03
Class 4 Medicines Defect Information: Sandoz Ltd., Rosuvastatin 20mg, 40mg Tablets, EL(24)A/45
Source: MHRA Published on 2024-10-01

FDA

Know Which Medication Is Right for Your Seasonal Allergies
Source: FDA Published on 2024-06-25
Sani-Care Salon Products, Inc. - 673747 - 04/24/2024
Source: FDA Published on 2024-06-25
Glenmark Pharmaceuticals Inc., USA Issues Voluntary Nationwide Recall for Potassium Chloride Extended-Release Capsules, USP (750 mg) 10 mEq K Due to Failed Dissolution
Source: FDA Published on 2024-06-25
Report | Drug Shortages: Root Causes and Potential Solutions
Source: FDA Published on 2024-06-24
FDA approves treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults
Source: FDA Published on 2024-06-24
Facilitating Generic Drug Product Development through Product-Specific Guidances - 04/25/2024
Source: FDA Published on 2024-06-24
Modernizing the New Drugs Regulatory Program
Source: FDA Published on 2024-06-24
FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
Source: FDA Published on 2024-06-21
Public Workshop: Best Practices for Meeting Management Under PDUFA VII - 07/22/2024
Source: FDA Published on 2024-06-21
Center for Drug Evaluation and Research National Survey on Numerical Claims in Prescription Drug Advertising
Source: FDA Published on 2024-06-20
Infla-650 contains hidden drug ingredients
Source: FDA Published on 2024-06-20
Cefdinir - Oral products
Source: FDA Published on 2024-06-20
Considerations in Demonstrating Interchangeability With a Reference Product: Update
Source: FDA Published on 2024-06-20
Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection
Source: FDA Published on 2024-06-20
FDA updates guidance on interchangeability
Source: FDA Published on 2024-06-20

Biosimilar-main-slider

Upcoming Events

News &
Events

Explore

Drag